Article

Behavior Genetics

, Volume 24, Issue 3, pp 285-297

First online:

Evidence for a multigenic system controlling methyl-β-carboline-3-carboxylate (β-CCM)-induced seizures

  • Benoît MartinAffiliated withGénétique, Neurogénétique et Comportement, URA 1294-CNRS, UFR Biomédicale Paris V
  • , Catherine MarchalandAffiliated withGénétique, Neurogénétique et Comportement, URA 1294-CNRS, UFR Biomédicale Paris V
  • , Georges ChapouthierAffiliated withGénétique, Neurogénétique et Comportement, URA 1294-CNRS, UFR Biomédicale Paris V
  • , Roland MottaAffiliated withLaboratoire de Recherche Génétique sur les Modèles Animaux (LRGMA) (CSAL)-CNRS

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

β-CCM is a β-carboline known to have properties opposite to those of benzodiazepines. Our approach was to analyze, in mice, the genetic mechanisms involved in β-CCM-induced myoclonic seizures using recombinant congenic strains and F1 hybrids issued from these strains. Our aim was to define the extent of the multigenic character of β-CCM-induced myoclonic seizures, while also evaluating the distribution of the strength of the genes implicated in this trait. The results show that the control of reactivity to β-CCM is multigenic with notable epistatic involvement.

Key Words

Recombinant congenic strains recombinant inbred strains β-carbolines methyl-β-carboline-3-carboxylate inverse agonist γ-aminobutyric acid mice